Human(ized) monoclonal antibodies in atopic patients - state of the art


Yalcin A. D. , Onbasi K. , Uzun R., Herth F., Schnabel P. A.

CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, vol.45, pp.195-201, 2020 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Review
  • Volume: 45
  • Publication Date: 2020
  • Doi Number: 10.5114/ceji.2020.97909
  • Title of Journal : CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
  • Page Numbers: pp.195-201

Abstract

Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use. The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.